Clinical Characteristics and Treatment of Irritable Bowel Syndrome in a Colombian Population: A Cross-Sectional Study.

IF 1.9 Q3 PHARMACOLOGY & PHARMACY Drugs - Real World Outcomes Pub Date : 2023-12-01 Epub Date: 2023-11-15 DOI:10.1007/s40801-023-00395-x
Daniel Andrés Hernández-Velásquez, Esteban Rodríguez-Martínez, Jhonathan David Montoya-Meneses, Juan Sebastián González-Ceballos, Katherin Mosquera-Pérez, Laura Patiño-Mazuera, Melissa González-Montoya, Andrés Gaviria-Mendoza, Jorge Enrique Machado-Alba
{"title":"Clinical Characteristics and Treatment of Irritable Bowel Syndrome in a Colombian Population: A Cross-Sectional Study.","authors":"Daniel Andrés Hernández-Velásquez, Esteban Rodríguez-Martínez, Jhonathan David Montoya-Meneses, Juan Sebastián González-Ceballos, Katherin Mosquera-Pérez, Laura Patiño-Mazuera, Melissa González-Montoya, Andrés Gaviria-Mendoza, Jorge Enrique Machado-Alba","doi":"10.1007/s40801-023-00395-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Irritable bowel syndrome (IBS) is a functional disorder that leads to abdominal pain; its diagnosis is based on Rome IV criteria (recurrent abdominal pain at least 1 day per week in the last 3 months with more than two of the following: related to defecation, associated with a change in stool frequency and/or with a change in stool appearance).</p><p><strong>Objective: </strong>To characterize an outpatient population diagnosed with IBS in Colombia during 2017-2018.</p><p><strong>Methods: </strong>A cross-sectional study based on a review of clinical records of patients with a primary diagnosis of IBS. A representative sample of 380 individuals was recruited from a population of 38,182 people with a new diagnosis of IBS from a drug-claim database. Sociodemographic, clinical (symptoms, type of IBS, alarm features, etc.), treatment (pharmacological or not), and follow-up variables (for those with additional medical care at 3-12 months) were analyzed. The diagnosis and treatment used in the consultation were compared with clinical guidelines.</p><p><strong>Results: </strong>Most of the 380 patients were women (n = 238; 62.6%), and the mean age was 40.1 ± 15.0 years. None of the physicians recorded the Rome IV criteria in the medical records. Unclassified IBS was the most prevalent subtype (n = 311; 81.8%), and the main symptom was abdominal pain (n = 327; 86.1%). Only 73 patients (19.2%) had follow-up data. The most frequently used drugs were aluminum hydroxide (n = 203; 53.4%) and hyoscine N-butyl bromide (n = 200; 52.6%). Regarding drugs included in the clinical practice guidelines, 19 people received loperamide (5.0%), 3 received trimebutine (0.8%), and 1 received sertraline (0.3%).</p><p><strong>Conclusions: </strong>The patients were diagnosed without clearly established criteria, and they were treated symptomatically with little follow-up.</p>","PeriodicalId":11282,"journal":{"name":"Drugs - Real World Outcomes","volume":" ","pages":"651-658"},"PeriodicalIF":1.9000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10730489/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drugs - Real World Outcomes","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40801-023-00395-x","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/11/15 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Irritable bowel syndrome (IBS) is a functional disorder that leads to abdominal pain; its diagnosis is based on Rome IV criteria (recurrent abdominal pain at least 1 day per week in the last 3 months with more than two of the following: related to defecation, associated with a change in stool frequency and/or with a change in stool appearance).

Objective: To characterize an outpatient population diagnosed with IBS in Colombia during 2017-2018.

Methods: A cross-sectional study based on a review of clinical records of patients with a primary diagnosis of IBS. A representative sample of 380 individuals was recruited from a population of 38,182 people with a new diagnosis of IBS from a drug-claim database. Sociodemographic, clinical (symptoms, type of IBS, alarm features, etc.), treatment (pharmacological or not), and follow-up variables (for those with additional medical care at 3-12 months) were analyzed. The diagnosis and treatment used in the consultation were compared with clinical guidelines.

Results: Most of the 380 patients were women (n = 238; 62.6%), and the mean age was 40.1 ± 15.0 years. None of the physicians recorded the Rome IV criteria in the medical records. Unclassified IBS was the most prevalent subtype (n = 311; 81.8%), and the main symptom was abdominal pain (n = 327; 86.1%). Only 73 patients (19.2%) had follow-up data. The most frequently used drugs were aluminum hydroxide (n = 203; 53.4%) and hyoscine N-butyl bromide (n = 200; 52.6%). Regarding drugs included in the clinical practice guidelines, 19 people received loperamide (5.0%), 3 received trimebutine (0.8%), and 1 received sertraline (0.3%).

Conclusions: The patients were diagnosed without clearly established criteria, and they were treated symptomatically with little follow-up.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
哥伦比亚人群肠易激综合征的临床特征和治疗:一项横断面研究。
背景:肠易激综合征(IBS)是一种导致腹痛的功能性疾病;其诊断基于Rome IV标准(过去3个月内每周至少1天复发性腹痛,伴有以下两项以上症状:与排便有关,伴排便频率改变和/或伴大便外观改变)。目的:分析2017-2018年哥伦比亚诊断为肠易激综合征的门诊人群的特征。方法:对初步诊断为肠易激综合征的患者的临床记录进行回顾性研究。从药物声明数据库中38182名新诊断为肠易激综合征的人群中招募了380名具有代表性的样本。分析了社会人口学、临床(症状、肠易激综合征类型、报警特征等)、治疗(药理学或非药理学)和随访变量(3-12个月时接受额外医疗护理的患者)。将会诊中采用的诊断和治疗方法与临床指南进行比较。结果:380例患者中以女性居多(n = 238;62.6%),平均年龄40.1±15.0岁。没有医生在医疗记录中记录罗马IV标准。未分类IBS是最常见的亚型(n = 311;81.8%),主要症状为腹痛(n = 327;86.1%)。只有73例患者(19.2%)有随访资料。最常使用的药物是氢氧化铝(n = 203;53.4%)和海莨菪碱n -丁基溴(n = 200;52.6%)。临床实践指南纳入的药物中,洛哌丁胺19人(5.0%),曲美布汀3人(0.8%),舍曲林1人(0.3%)。结论:患者诊断无明确标准,对症治疗,随访少。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Drugs - Real World Outcomes
Drugs - Real World Outcomes PHARMACOLOGY & PHARMACY-
CiteScore
3.60
自引率
5.00%
发文量
49
审稿时长
8 weeks
期刊介绍: Drugs - Real World Outcomes targets original research and definitive reviews regarding the use of real-world data to evaluate health outcomes and inform healthcare decision-making on drugs, devices and other interventions in clinical practice. The journal includes, but is not limited to, the following research areas: Using registries/databases/health records and other non-selected observational datasets to investigate: drug use and treatment outcomes prescription patterns drug safety signals adherence to treatment guidelines benefit : risk profiles comparative effectiveness economic analyses including cost-of-illness Data-driven research methodologies, including the capture, curation, search, sharing, analysis and interpretation of ‘big data’ Techniques and approaches to optimise real-world modelling.
期刊最新文献
Correction: Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study. Correction: Falls and Fractures Among Nursing Home Residents Treated with Pimavanserin Versus Other Atypical Antipsychotics: Analysis of Medicare Beneficiaries with Parkinson's Disease Psychosis. Effects of the Japanese Kampo Medicines Rikkunshito, Shakuyakukanzoto and Goreisan on Lenvatinib Plasma Concentrations in Japanese Patients with Thyroid Cancer. Determinants of the Financial Impact of Orphan Drugs in Italy: Differences Between Expected and Observed Pharmaceutical Expenditure. Medication Errors and Error Chains Involving High-Alert Medications in a Paediatric Hospital Setting: A Qualitative Analysis of Self-Reported Medication Safety Incidents.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1